治疗后1型自身免疫性胰腺炎的胰胆管受累:影像表现模式与疾病复发危险因素
基于前瞻性临床影像数据库纳入103例治疗后1型自身免疫性胰腺炎患者,44例(42.7%)随访期间出现胰胆管病灶,均为疾病复发并对激素治疗有反应;复发时胰腺受累较少见(81.8% vs 100%,p=0.003)且胰腺体积更小(p<0.01),而胰外胆管受累更严重广泛(均p<0.01)。初诊时胰外胆管受累(HR 2.437,95%CI 1.343-7.402,p=0.002)和诱导期血清IgG4反应比(HR 0.357,95%CI 0.055-0.804,p=0.011)为复发的独立预测因素。
要点
- 治疗后1型自身免疫性胰腺炎随访中新出现的胰胆管病灶应首先考虑疾病复发,而非新发肿瘤。
- 复发时胰腺受累比例低于初诊(81.8% vs 100%),胰腺体积较初诊缩小(p<0.01)。
- 复发时胰外胆管受累较初诊更严重、范围更广(均p<0.01),阅片需重点评估胆管。
核心结论
- 治疗后1型自身免疫性胰腺炎患者随访中出现的胰胆管病灶通常为疾病复发表现,虽影像模式可与初诊不同。
- 初诊时存在胰外胆管受累及诱导期血清IgG4反应不佳提示复发风险高。
研究设计与样本
- 研究经机构审查委员会批准,所有患者签署书面知情同意。
- 自2012年起从前瞻性临床影像数据库连续纳入接受治疗并随访至少18个月(≥18个月)的1型自身免疫性胰腺炎患者,共103例。
- 评估随访期间胰胆管病灶的有无,确定病因并将影像模式与初发发作比较,采用单因素和多因素分析识别危险因素。
关键影像表现/征象
- 随访中44例(42.7%)出现胰胆管病灶,距初诊中位时间17个月(范围3-62个月)。
- 病灶多出现于停用激素后(63.6%)或维持治疗期间(29.5%)。
- 复发时胰腺受累较初诊少见(81.8% vs 100%,p=0.003),胰腺体积较初诊缩小(p<0.01)。
- 复发时胰外胆管受累较初诊更严重且范围更广(均p<0.01)。
诊断标准与关键数值
- 所有随访中新出现的胰胆管病灶均判定为疾病复发,并对激素治疗有反应。
- 多因素分析显示初诊时胰外胆管受累为复发的独立预测因素(HR 2.437,95%CI 1.343-7.402,p=0.002)。
- 诱导期血清IgG4反应比为复发的独立预测因素(HR 0.357,95%CI 0.055-0.804,p=0.011)。
临床应用与阅片要点
- 随访中新出现胰胆管病灶时,应结合初诊胰外胆管受累情况及诱导期血清IgG4反应比评估复发风险。
- 复发时胰腺体积缩小、胰腺受累比例下降而胰外胆管病变更重更广,阅片时需注意与初诊影像模式不同。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the imaging pattern of pancreaticobiliary lesions in patients with treated type 1AIP, to determine the incidence of disease relapse and malignancy, and to identify the risk factors.
METHOD: The institutional review board approval was acquired. All patients gave written informed consent. From a prospective clinico-radiological database since 2012, consecutive patients with type 1 AIP who were treated and followed up (≥18 months) were identified. The presence/absence of pancreaticobiliary lesion(s) development during follow-up were assessed. The etiology was determined and the imaging pattern was compared to the initial attack. Risk factors were identified by univariate and multivariate analysis.
RESULTS: Among 103 patients with treated type 1 AIP, 44 (42.7%) developed pancreaticobiliary lesions during follow up (median time interval to initial diagnosis: 17 months, range 3-62 months), mostly after steroid discontinuation (63.6%) or during maintenance therapy (29.5%). All lesions were disease relapse, which responded to steroid treatment. At relapse, pancreatic involvement was less frequent (81.8% vs 100%, p = 0.003), and the pancreas size was smaller (p < 0.01), whereas extra-pancreatic bile duct (ExPanBD) involvement was more severe and extensive (both p < 0.01). Multivariate analysis revealed ExPanBD involvement at initial diagnosis (hazard ratio 2.437, 95% CI 1.343-7.402, p = 0.002) and serum IgG4 response ratio at the induction phase (hazard ratio 0.357, 95% CI 0.055-0.804, p = 0.011) as significant independent predictors of relapse.
CONCLUSIONS: In treated type 1 AIP, although imaging pattern may differ, pancreaticobiliary lesions are usually manifestations of disease relapse. ExPanBD involvement and poor serum response suggests high risk of relapse.
引用
- Zhu L, Xue HD, Zhang W, et al. Pancreaticobiliary involvement in treated type 1 autoimmune pancreatitis: Imaging pattern and risk factors for disease relapse. Eur J Radiol. 2019. PMID: 31550640. doi:10.1016/j.ejrad.2019.108673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。